Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

472.80 +1.68 (+0.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
53 54 Next >
2 Growth Stocks That Could Double in 5 Years
Both of these companies did more than that in the past five years. 
Via The Motley Fool
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Cash-Rich Biotech Stocks to Bet on for the Long Haul
Cash rich biotech stocks can survive while most of their peers struggle with rising interest rates. Here are three to watch. 
Via InvestorPlace
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Why CRISPR Therapeutics Stock Is Marching Higher Today
This gene-editing stock has been heating up over the past week. 
Via The Motley Fool
Is CRISPR Therapeutics Stock a Buy Now?
The biotech could soon be a commercial-stage company. 
Via The Motley Fool
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Healthcare Stocks That Could Help Make You a Fortune
These companies are top players in their fields. 
Via The Motley Fool
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
Via Benzinga
The Best Stocks to Invest $20,000 in Right Now
You'll want to hold on to these top stocks for the long term. 
Via The Motley Fool
Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc. 
Via Benzinga
Better Big Biotech Buy: Biogen vs. Vertex
One is slightly cheaper than the other. 
Via The Motley Fool
Have $1,000? 2 Explosive Growth Stocks to Buy and Hold No Matter What the Market Does Next
A volatile market can be an investor's friend. 
Via The Motley Fool
Got $5,000? Buy and Hold These Fast-Growing Stocks for Years
These companies have doubled their sales within the past five years. 
Via The Motley Fool
3 High-Growth Biotech Stocks Poised for Success in 2023
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
The Fed Thinks a Recession Is More Likely: Here Are 3 Great Stocks to Buy Now
These stocks should hold up quite well regardless of what happens with the U.S. economy. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
A small investment now may bring big results over time. 
Via The Motley Fool
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before. 
Via Investor's Business Daily
Why Shares of Editas Medicine Rose Monday
The company is benefiting from positive news affecting other gene-editing stocks. 
Via The Motley Fool
Which Stocks Pass Warren Buffett's $10,000 Test?
Buffett's recent CNBC interview raises an interesting question. 
Via The Motley Fool
Prediction: These Will Be 3 of the Biggest Monster Stocks of the Decade
They're already highly successful. But there's a lot more room to run. 
Via The Motley Fool
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Records 52-Week High Thursday Morning
Via Investor Brand Network
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
Via Benzinga
2 Nasdaq Growth Stocks That Are Screaming Buys in April
Massive drivers of fresh earnings are drawing closer, and risks are declining. 
Via The Motley Fool
Moderna, ConocoPhillips, Vertex Pharmaceuticals And This ETF: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Anastasia Amoroso of JP Morgan Private Bank named iShares Preferred and Income Securities ETF (NYSE: PFF) as her 
Via Benzinga
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
Could This Move Make Vertex's Next Blockbuster Even Bigger?
Vertex is showing it can branch out beyond its cystic fibrosis specialty. 
Via The Motley Fool
Vertex to Announce First Quarter 2023 Financial Results on May 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.